Mesoblast

Mesoblast

Yahoo Finance • 3 days ago

Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients trea... Full story

Yahoo Finance • 16 days ago

Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) fi... Full story

Yahoo Finance • 22 days ago

Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility

Optimized capital structure, retiring short-term maturing debt Well-funded for commercial operations and growth pipeline NEW YORK, June 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic... Full story

Yahoo Finance • 3 months ago

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB)... Full story

Yahoo Finance • 3 months ago

Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Mesoblast share move and recent return profile Mesoblast (ASX:MSB) recently closed at A$2.15, catching attention afte... Full story

Yahoo Finance • 3 months ago

Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain

NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemest... Full story

Yahoo Finance • 3 months ago

Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why

With strong revenue growth projections, Mesoblast Limited (NASDAQ:MESO) secures a spot on our list of the best long-term ASX stocks to buy right now.Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why... Full story

Yahoo Finance • 3 months ago

Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up

(RTTNews) - Mesoblast Limited (MESO, MSB.AX) announced the acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform. This innovation is designed to enhance the precision and effectiven... Full story

Yahoo Finance • 3 months ago

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a pat... Full story

Yahoo Finance • 3 months ago

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION

Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limi... Full story

Yahoo Finance • 3 months ago

Mesoblast Wins FDA IND Clearance To Fast-Track Ryoncil Trial In Duchenne Muscular Dystrophy

(RTTNews) - Mesoblast Limited (MESO), a commercial-stage biotechnology firm, announced that the United States Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance to directly proceed with a registrational... Full story

Yahoo Finance • 3 months ago

Mesoblast Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO;... Full story

Yahoo Finance • 3 months ago

Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter

Strong growth in February/March following January seasonality Net revenue approaches US$100M since launch NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medic... Full story

Yahoo Finance • 4 months ago

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron (NASDAQ: LGVN) Key Takeaways: • Avaí B... Full story

Yahoo Finance • 4 months ago

Mesoblast to Host R&D Day on April 8, 2026

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host its inaugural R&D Day on Wednesday, April 8, 2026 in New York City... Full story

Yahoo Finance • 4 months ago

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly esta... Full story

Yahoo Finance • 5 months ago

Ryoncil® Profits Underpinning Substantial Growth Pipeline

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period end... Full story

Yahoo Finance • 7 months ago

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

Mesoblast has option to draw down up to US$125 million by June 30, 2026 New facility does not encumber any of Mesoblast's material assets or intellectual property NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:ME... Full story

Yahoo Finance • 7 months ago

Mesoblast (MESO) Sees Optimism From Analysts

We recently published 7 Best ASX Stocks to Buy Right Now.  Mesoblast Limited (NASDAQ:MESO) is one of the best ASX stocks. Mesoblast Limited (NASDAQ:MESO) is a biotechnology company developing treatments for inflammatory diseases, heart fa... Full story

Yahoo Finance • 7 months ago

Mesoblast Participation at Piper Sandler Conference

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare... Full story